Jointown: The holder of the marketing authorization for Dopamine Hydrochloride Injection has been changed to Huiyu Yuanhe
Jointown announced that its subsidiary Beijing Jingfeng Pharmaceutical Group's subsidiary Huiyu Yuanhe Pharmaceutical Co., Ltd. received the "Drug Supplement Application Approval Notice" approved and issued by the National Medical Products Administration on October 24, 2025, approving the change of the marketing authorization holder for Dopamine Hydrochloride Injection to Huiyu Yuanhe. This drug is mainly used for shock syndromes caused by myocardial infarction, trauma, and other conditions, as well as heart failure. In 2024, the sales of Dopamine Hydrochloride Injection in hospitals reached 175 million yuan
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments